Eventide Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Eventide Asset Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-23,185	Closed	-$2.92M	–	152
2017 Q4	$2.92M	Hold	23,185	–	–	0.15%	95
2017 Q3	$3.17M	Sell	23,185 -6,815	-23%	-$912K	0.18%	89
2017 Q2	$4.28M	Hold	30,000	–	–	0.27%	76
2017 Q1	$5.51M	Hold	30,000	–	–	0.37%	70
2016 Q4	$2.42M	Hold	30,000	–	–	0.16%	93
2016 Q3	$2.3M	Hold	30,000	–	–	0.14%	93
2016 Q2	$2.58M	Buy	+30,000	New	+$2.75M	0.16%	92
2016 Q1	–	Sell	-6,965	Closed	-$1.4M	–	143
2015 Q4	$1.4M	Sell	6,965 -1,735	-20%	-$346K	0.07%	106
2015 Q3	$1.3M	Sell	8,700 -5,800	-40%	-$4.26M	0.08%	105
2015 Q2	$13.8M	Hold	14,500	–	–	0.74%	48
2015 Q1	$10.6M	Hold	14,500	–	–	0.8%	49
2014 Q4	$11.5M	Sell	14,500 -545	-4%	-$293K	1.26%	31
2014 Q3	$6M	Hold	15,045	–	–	0.84%	52
2014 Q2	$4.06M	Hold	15,045	–	–	0.55%	62
2014 Q1	$3.28M	Buy	15,045 +10,215	+211%	+$2.85M	0.51%	60
2013 Q4	$1.31M	Buy	+4,830	New	+$1.15M	0.4%	56

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Eventide Asset Management's TTPH Position: Q1 2018 in Review

Eventide Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 23,185 shares — an estimated $2.92M sold.

Eventide Asset Management first reported a position in TTPH in Q4 2013 and held it in 16 quarters. The position peaked at $13.8M in Q2 2015. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

Eventide Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Eventide Asset Management sold 23,185 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2.92M.
Eventide Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 16 quarters.
Eventide Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $13.8M in Q2 2015.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Eventide Asset Management's 13F filing for Q1 2018, filed 15 May 2018.